Waltham-based company to exhibit its wearable device for widespread
pain relief
ORLANDO, Fla.--(BUSINESS WIRE)--
Coming together with thousands of leading clinicians who treat patients
with chronic pain, NeuroMetrix,
Inc. (Nasdaq: NURO) will exhibit Quell®,
its FDA-cleared, 100% drug-free wearable designed to provide widespread
relief from chronic pain, at the American Academy of Pain Medicine
(AAPM) 33rd
Annual Meeting in Orlando, Fla., March 15-19, 2017 at booth #418.
The theme of this year's AAPM annual meeting is "Pain as a Public Health
Issue," and will cover educational content around the pressing need for
pain clinicians to address this major public health burden through
evidence-based treatments in practice. With nearly 100 million Americans
living with chronic pain, and an estimated $635 billion spent a year on
chronic pain management, NeuroMetrix is dedicated to meaningful
innovation and bringing relief to those living with chronic pain with
the latest technology.
"For one in three Americans, chronic pain continues to disrupt their
everyday life, and they are continually looking to their clinicians for
alternative treatments to alleviate their pain," said Shai N. Gozani,
M.D., Ph.D. "Quell empowers those living with chronic pain to reclaim
their life through advanced technology. We're looking forward to
connecting with leading pain clinicians at this year's meeting to bring
more awareness to technological alternatives that can be shared with
their patients."
Quell combines advanced neurotechnology in a wearable format with a
sophisticated app for users to personalize and control therapy, while
tracking their pain and relevant health metrics. The product has made a
difference in tens of thousands of lives since its introduction in 2015.
In a clinical study published last year in the Journal of Pain Research,
81 percent of subjects reported improvement in their chronic pain, and
67 percent reported a reduction in their use of pain medication after 60
days of using Quell.
The AAPM 33rd Annual Meeting will be held March 15-19, 2017
at the Loews Sapphire Falls Resort at Universal Orlando in Orlando, Fla.
Attendees can learn more about Quell by visiting the NeuroMetrix booth,
#418 during the conference and following along on Twitter @Quellrelief.
About Quell
Quell is designed for millions of people suffering from chronic pain.
The advanced wearable device is lightweight and can be worn during the
day while active, and at night while sleeping. It has been cleared by
the FDA for treatment of chronic pain without a prescription. In a
recent study, 81% of Quell users reported an improvement in their
chronic pain. Quell users can personalize and manage therapy discreetly
via the Quell Relief app. Quell also offers advanced health tracking
relevant to chronic pain sufferers including pain, sleep, activity, and
gait. Quell was the winner of the 2016 SXSW (South by Southwest)
Innovation Award for Best Wearable Technology. Quell is available at
select healthcare professionals and retailers. Visit QuellRelief.com
for more information.
About NeuroMetrix
NeuroMetrix is a commercial stage, innovation driven healthcare company
combining bioelectrical and digital medicine to address chronic health
conditions including chronic pain, sleep disorders, and diabetes. The
company's lead product is Quell, an over-the-counter wearable
therapeutic device for chronic pain. Quell is integrated into a digital
health platform that helps patients optimize their therapy and decrease
the impact of chronic pain on their quality of life. The company also
markets DPNCheck®, a rapid point-of-care test for diabetic
neuropathy, which is the most common long-term complication of Type 2
diabetes. The company maintains an active research effort and has
several pipeline programs. The company is located in Waltham,
Massachusetts and was founded as a spinoff from the Harvard-MIT Division
of Health Sciences and Technology in 1996. For more information, please
visit www.NeuroMetrix.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170315006016/en/
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and
Chief Financial Officer
neurometrix.ir@neurometrix.com
Source: NeuroMetrix, Inc.
News Provided by Acquire Media
